India Biomarker Technologies Market

India Biomarker Technologies Market Research Report: By Product (Consumables, Instruments), By Profiling Technology (PCR, Imaging Technology, NGS), By Application (Cancer, Infectious Disease) andBy Research Area (Genomics, Proteomics)- Forecast to 2035

Forecast Period
2025 - 2035
CAGR
8.01%
2018 Market Size
$ 1.39 Billion
2035 Market Size
$ 5.26 Billion
Healthcare ● Updated March 28, 2026 Report ID: MRFR/HC/54489-HCR | Pages: 200 | Author: Vikita Thakur

India Biomarker Technologies Market Summary

As per MRFR analysis, the India Biomarker Technologies Market was estimated at 2.25 USD Billion in 2024. The biomarker technologies industry is projected to grow from 2.43 in 2025 to 5.26 by 2035, exhibiting a compound annual growth rate (CAGR) of 8.01 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The India Biomarker Technologies Market is poised for substantial growth driven by technological advancements and increasing healthcare investments.

  • The market is witnessing a rising demand for personalized medicine, particularly in oncology and genetic disorders.
  • Technological advancements in diagnostics are enhancing the accuracy and efficiency of biomarker detection methods.
  • The largest segment in the market is oncology, while the fastest-growing segment is genetic testing, reflecting evolving healthcare needs.
  • Key market drivers include the growing prevalence of chronic diseases and increasing investment in healthcare infrastructure.

Market Size & Forecast

2024 Market Size 2.25 (USD Billion)
2035 Market Size 5.26 (USD Billion)
CAGR (2025 - 2035) 8.01%

Major Players

Thermo Fisher Scientific (US), Roche Diagnostics (CH), Abbott Laboratories (US), Agilent Technologies (US), Bio-Rad Laboratories (US), Merck KGaA (DE), Illumina (US), Qiagen (DE), PerkinElmer (US)

Our Impact

Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals

Partnering with 2000+ Global Organizations Each Year

30K+ Citations by Top-Tier Firms in the Industry

India Biomarker Technologies Market Drivers

Advancements in Genomic Research

The rapid advancements in genomic research are significantly influencing the India Biomarker Technologies Market. With the advent of next-generation sequencing and other genomic technologies, researchers are uncovering new biomarkers that can aid in disease diagnosis and treatment. The Indian government has recognized the importance of genomics in healthcare, launching initiatives to promote research and development in this field. For instance, the Department of Biotechnology has been actively funding projects aimed at identifying genetic markers for various diseases. This influx of research funding is expected to accelerate the discovery of novel biomarkers, thereby expanding the market. As genomic data becomes more accessible, the potential for personalized medicine based on biomarker identification is likely to reshape treatment paradigms in India.

Growing Prevalence of Chronic Diseases

The increasing incidence of chronic diseases in India is a pivotal driver for the India Biomarker Technologies Market. Conditions such as diabetes, cardiovascular diseases, and cancer are on the rise, necessitating advanced diagnostic tools. According to the Indian Council of Medical Research, the prevalence of diabetes is projected to reach 134 million by 2045. This alarming trend underscores the need for biomarkers that can facilitate early detection and personalized treatment plans. As healthcare providers seek to improve patient outcomes, the demand for biomarker technologies is likely to surge, propelling market growth. Furthermore, the integration of biomarker testing in routine clinical practice could enhance disease management and monitoring, thereby fostering a more proactive healthcare approach in India.

Rising Awareness of Preventive Healthcare

The growing awareness of preventive healthcare among the Indian population is a notable driver for the India Biomarker Technologies Market. As individuals become more health-conscious, there is an increasing demand for early detection and preventive measures against diseases. Educational campaigns and health initiatives by the government have played a vital role in promoting the importance of regular health screenings and biomarker testing. This shift towards preventive healthcare is likely to drive the adoption of biomarker technologies, as they offer valuable insights into an individual's health status. Furthermore, the rise of health tech startups focusing on biomarker-based solutions is indicative of this trend. As awareness continues to grow, the market for biomarker technologies in India is expected to expand, catering to the needs of a more informed consumer base.

Regulatory Support for Innovative Diagnostics

Regulatory support for innovative diagnostics is emerging as a significant driver for the India Biomarker Technologies Market. The Central Drugs Standard Control Organization (CDSCO) has been working towards streamlining the approval process for diagnostic tests, including those based on biomarkers. This regulatory facilitation is crucial for encouraging innovation and bringing new biomarker technologies to market. Additionally, the government has been promoting initiatives such as the Make in India campaign, which aims to boost domestic manufacturing of diagnostic devices. As regulatory hurdles diminish, companies are likely to invest more in research and development of biomarker technologies, leading to a more dynamic market landscape. This supportive regulatory environment could potentially enhance the availability of cutting-edge diagnostic solutions in India.

Increasing Investment in Healthcare Infrastructure

The ongoing investment in healthcare infrastructure in India is a crucial driver for the India Biomarker Technologies Market. The government has been allocating substantial resources to enhance healthcare facilities, particularly in rural areas. The National Health Mission aims to strengthen healthcare delivery systems, which includes the integration of advanced diagnostic technologies. As healthcare facilities upgrade their capabilities, the demand for biomarker technologies is expected to rise. Moreover, private sector investments in healthcare are also on the rise, with numerous startups focusing on biomarker development and diagnostics. This collaborative effort between public and private sectors is likely to create a conducive environment for the growth of biomarker technologies, ultimately improving patient care and outcomes.

Market Segment Insights

By Application: Oncology (Largest) vs. Cardiology (Fastest-Growing)

The Application segment of the India Biomarker Technologies Market is diverse, with Oncology holding the largest share. This dominance is attributed to the increasing prevalence of cancer cases and the pivotal role of biomarkers in early detection and personalized treatment plans. In contrast, Cardiology is emerging as a fast-growing segment, driven by rising cardiovascular disorders in the Indian population and the growing emphasis on early diagnostic technologies to effectively manage heart diseases.

India Biomarker Technologies Market Segment Image 0

Oncology: Dominant vs. Cardiology: Emerging

Oncology represents a dominant segment in the India Biomarker Technologies Market owing to the rising incidence of cancer, which has necessitated advancements in biomarkers for early diagnosis and personalized therapy. In line with this trend, significant investments in oncology research and development are being witnessed. Meanwhile, Cardiology, categorized as an emerging segment, is experiencing rapid growth attributed to the increasing burden of cardiovascular diseases. The introduction of innovative biomarker-based diagnostics is enhancing the capabilities for monitoring heart conditions, thus catering to the urgent health challenges faced in urban and rural settings.

By Technology: Genomics (Largest) vs. Proteomics (Fastest-Growing)

India Biomarker Technologies Market Segment Image 1

In the India Biomarker Technologies Market, the Genomics segment holds the largest share, indicating its critical role in genetic research and precision medicine. This segment has established itself as the backbone of biomarker discoveries, driven by advancements in sequencing technologies and a growing focus on personalized healthcare. The Proteomics segment, on the other hand, is emerging rapidly and displays the fastest growth, propelled by innovations in mass spectrometry and an increasing emphasis on protein-based diagnostics.

Genomics (Dominant) vs. Proteomics (Emerging)

The Genomics segment remains dominant in the India Biomarker Technologies Market, thanks to its pivotal role in understanding genetic predispositions and facilitating targeted therapeutics. Companies are investing heavily in genomics research, attracted by its potential to provide insights into complex diseases. Conversely, the Proteomics segment is recognized as an emerging field, flourishing due to its capacity to uncover protein interactions and functions, which are instrumental in biomarker identification. The rapid adoption of proteomic technologies, coupled with heightened research funding, is expected to solidify its position as a key player in the market.

By End Use: Pharmaceutical Companies (Largest) vs. Diagnostic Laboratories (Fastest-Growing)

In the India Biomarker Technologies Market, the segment distribution reveals that pharmaceutical companies hold the largest share, utilizing biomarker technologies primarily for drug discovery and clinical trials. Research institutions also play a significant role, contributing to the overall market with innovative research and development efforts. Diagnostic laboratories, while smaller in overall market share currently, are rapidly expanding their use of these technologies for enhanced diagnostic capabilities, thus revealing a dynamic interplay in market demand. In terms of growth trends, pharmaceutical companies continue to invest heavily in biomarker technologies to optimize drug development processes, while diagnostic laboratories are experiencing the fastest growth due to the increasing demand for accurate and efficient diagnostics in healthcare. Research institutions also contribute to growth by fostering innovation, often partnering with commercial entities to bring cutting-edge solutions to market. This combined momentum indicates a robust environment for biomarker technology advancements across these segments.

India Biomarker Technologies Market Segment Image 2

Pharmaceutical Companies (Dominant) vs. Contract Research Organizations (Emerging)

Pharmaceutical companies are the dominant players in the India Biomarker Technologies Market, leveraging biomarker advancements to streamline their drug development processes and ensure high efficacy and safety profiles. They engage in extensive research to discover novel biomarkers that can predict drug responses, significantly enhancing their capability in personalized medicine. On the other hand, Contract Research Organizations (CROs) present as an emerging segment, capitalizing on the growing demand for outsourced research services. These organizations provide essential support to pharmaceutical companies, offering expertise in biomarker development and validation, thus playing a critical role in accelerating clinical trials and enhancing productivity in drug development.

By Type: Biomarkers for Disease Diagnosis (Largest) vs. Predictive Biomarkers (Fastest-Growing)

India Biomarker Technologies Market Segment Image 3

In the India Biomarker Technologies Market, the segment of Biomarkers for Disease Diagnosis holds the largest share, showcasing its critical role in healthcare. This segment leverages advanced technology to identify diseases at an early stage, thus significantly enhancing patient outcomes. On the other hand, Predictive Biomarkers are rapidly gaining traction, driven by the increasing demand for personalized medicine and precision treatments, indicating a shift towards more individualized approaches in disease management.

Biomarkers for Disease Diagnosis (Dominant) vs. Predictive Biomarkers (Emerging)

Biomarkers for Disease Diagnosis serve as the cornerstone of the India Biomarker Technologies Market, offering robust solutions for early detection and accurate diagnosis of various conditions. Their established presence in clinical applications underscores their dominance. In contrast, Predictive Biomarkers are an emerging segment, fueled by innovations that enable the anticipation of disease progression and response to treatment. With the healthcare sector's progressive shift towards personalized medicine, Predictive Biomarkers are poised to revolutionize patient care by tailoring interventions based on individual genetic and biological profiles.

Get more detailed insights about India Biomarker Technologies Market Request Free Sample

Key Players and Competitive Insights

The India Biomarker Technologies Market is currently characterized by a dynamic competitive landscape, driven by advancements in precision medicine, increasing prevalence of chronic diseases, and a growing emphasis on personalized healthcare. Major players such as Thermo Fisher Scientific (US), Roche Diagnostics (CH), and Abbott Laboratories (US) are strategically positioned to leverage these trends. For instance, Thermo Fisher Scientific (US) focuses on innovation through its extensive portfolio of biomarker discovery and validation tools, while Roche Diagnostics (CH) emphasizes partnerships with local research institutions to enhance its diagnostic capabilities. Abbott Laboratories (US) is also actively pursuing regional expansion, particularly in tier-2 and tier-3 cities, to tap into the burgeoning demand for biomarker technologies. Collectively, these strategies contribute to a competitive environment that is increasingly collaborative yet fiercely competitive.

Key business tactics within the market include localizing manufacturing and optimizing supply chains to enhance operational efficiency. The competitive structure appears moderately fragmented, with a mix of established players and emerging startups. This fragmentation allows for diverse offerings and innovation, as smaller firms often introduce niche technologies that challenge the status quo. The collective influence of key players is significant, as they not only set industry standards but also drive research and development initiatives that shape market trends.

In January 2026, Roche Diagnostics (CH) announced a strategic partnership with a leading Indian biotechnology firm to co-develop next-generation biomarker assays. This collaboration is poised to enhance Roche's product offerings in the Indian market, allowing for faster and more accurate diagnostics tailored to local healthcare needs. The strategic importance of this partnership lies in its potential to accelerate the development of innovative solutions that address specific regional health challenges, thereby solidifying Roche's market position.

In December 2025, Abbott Laboratories (US) launched a new biomarker-based diagnostic tool aimed at early detection of cardiovascular diseases in India. This launch is significant as it aligns with the increasing focus on preventive healthcare in the region. By introducing this tool, Abbott not only expands its product portfolio but also reinforces its commitment to addressing the rising burden of cardiovascular diseases, which are a leading cause of mortality in India.

In November 2025, Thermo Fisher Scientific (US) unveiled a new manufacturing facility in India dedicated to the production of biomarker technologies. This facility is expected to enhance local production capabilities and reduce lead times for customers. The strategic importance of this investment lies in its potential to improve supply chain reliability and responsiveness, which are critical factors in the rapidly evolving healthcare landscape.

As of February 2026, current competitive trends in the India Biomarker Technologies Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) into diagnostic processes. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation and expanding market reach. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological innovation, reliability of supply chains, and the ability to deliver personalized healthcare solutions. This shift underscores the importance of agility and responsiveness in a market that is rapidly changing.

Key Companies in the India Biomarker Technologies Market include

Industry Developments

Recent developments in the India Biomarker Technologies Market include significant strides in diagnostic and therapeutic solutions. Agilent Technologies and Thermo Fisher Scientific are advancing initiatives targeted at precision medicine, while Merck Group is actively expanding its portfolio in genomics. Abbott Laboratories has invested in R&D to enhance biomarker identification, aligning with the growing demand for personalized healthcare. In the past year, the market has witnessed a substantial increase in demand for innovative biomarkers, driven by a rise in chronic diseases and a surge in healthcare expenditure. Notably, in August 2023, GE Healthcare announced a strategic collaboration with QIAGEN to develop integrated diagnostic solutions, emphasizing the importance of biomarker technologies in disease management. Companies like F. HoffmannLa Roche and Siemens Healthineers are also investing in digital health solutions to streamline biomarker testing. Furthermore, BioRad Laboratories has reported strong financial growth, driven by their advancements in multiplex biomarker assays. The Indian government’s initiatives to promote biotechnology and health research continue to bolster market dynamics, highlighting the importance of ongoing cooperation between industry stakeholders and the public sector to address healthcare challenges.

Future Outlook

India Biomarker Technologies Market Future Outlook

The India Biomarker Technologies Market is projected to grow at 8.01% CAGR from 2024 to 2035, driven by advancements in personalized medicine, increased R&D investments, and rising healthcare demands.

New opportunities lie in:

  • Development of point-of-care diagnostic devices for rapid biomarker testing.
  • Expansion of biomarker-based companion diagnostics in oncology treatments.
  • Integration of AI-driven analytics for enhanced biomarker discovery and validation.

By 2035, the market is expected to achieve substantial growth, positioning India as a leader in biomarker technologies.

Market Segmentation

India Biomarker Technologies Market Type Outlook

  • Biomarkers for Disease Diagnosis
  • Biomarkers for Drug Development
  • Companion Diagnostics
  • Predictive Biomarkers

India Biomarker Technologies Market End Use Outlook

  • Pharmaceutical Companies
  • Research Institutions
  • Diagnostic Laboratories
  • Contract Research Organizations

India Biomarker Technologies Market Technology Outlook

  • Genomics
  • Proteomics
  • Metabolomics
  • Immunoassays
  • Bioinformatics

India Biomarker Technologies Market Application Outlook

  • Oncology
  • Cardiology
  • Neurology
  • Infectious Diseases
  • Metabolic Disorders

Report Scope

Report Scope:

Report Attribute/Metric Source: Details
MARKET SIZE 2018 1.39(USD Billion)
MARKET SIZE 2024 1.8(USD Billion)
MARKET SIZE 2035 5.4(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR) 10.503% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
MARKET FORECAST PERIOD 2025 - 2035
HISTORICAL DATA 2019 - 2024
MARKET FORECAST UNITS USD Billion
KEY COMPANIES PROFILED Agilent Technologies, Merck Group, Abbott Laboratories, Medtronic, Thermo Fisher Scientific, PerkinElmer, QIAGEN, BristolMyers Squibb, BioRad Laboratories, F. HoffmannLa Roche, Roche Diagnostics, Siemens Healthineers, GE Healthcare, Illumina
SEGMENTS COVERED Product, Profiling Technology, Application, Research Area
KEY MARKET OPPORTUNITIES Growing demand for personalized medicine, Increasing prevalence of chronic diseases, Advancements in diagnostic technologies, Government support for research initiatives, Expanding biopharmaceutical sector investments
KEY MARKET DYNAMICS Technological advancements, Increasing prevalence of diseases, Rising research and development investments, Growing demand for personalized medicine, Government support and funding
COUNTRIES COVERED India

FAQs

What is the current valuation of the India Biomarker Technologies Market?

As of 2024, the market valuation was 2.25 USD Billion.

What is the projected market size for the India Biomarker Technologies Market by 2035?

The market is projected to reach 5.26 USD Billion by 2035.

What is the expected CAGR for the India Biomarker Technologies Market during the forecast period 2025 - 2035?

The expected CAGR for the market during this period is 8.01%.

Which application segments are driving growth in the India Biomarker Technologies Market?

Key application segments include Oncology, Cardiology, and Neurology, with Oncology valued at 0.9 USD Billion in 2024.

What technologies are contributing to the India Biomarker Technologies Market?

Technologies such as Genomics and Bioinformatics are significant, with Bioinformatics valued at 1.0 USD Billion in 2024.

Who are the leading players in the India Biomarker Technologies Market?

Key players include Thermo Fisher Scientific, Roche Diagnostics, and Abbott Laboratories.

What are the primary end-use segments in the India Biomarker Technologies Market?

Pharmaceutical Companies and Diagnostic Laboratories are primary end-users, with Pharmaceutical Companies valued at 0.9 USD Billion in 2024.

What types of biomarkers are being utilized in the India Biomarker Technologies Market?

Biomarkers for Disease Diagnosis and Drug Development are prominent, with Disease Diagnosis valued at 0.9 USD Billion in 2024.

How does the market for Infectious Diseases compare to other segments?

The market for Infectious Diseases was valued at 0.3 USD Billion in 2024, indicating potential for growth.

What is the growth outlook for the Bioinformatics segment in the India Biomarker Technologies Market?

The Bioinformatics segment is projected to grow from 1.0 USD Billion in 2024 to 1.36 USD Billion by 2035.

Author
Author
Author Profile
Vikita Thakur LinkedIn
Senior Research Analyst
She holds an experience of about 5+ years in market research and business consulting projects for sectors such as life sciences, medical devices, and healthcare IT. She possesses a robust background in data analysis, market estimation, competitive intelligence, pipeline analysis market trend identification, and consumer behavior insights. Her expertise lies in technical Sales support, client interaction and project management, designing and implementing market research studies, conducting competitive analysis, and synthesizing complex data into actionable recommendations that drive business growth.
Share::
Request Free Sample
Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Share::
Request Free Sample
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.